Articles tagged with Lung Tumors
Researchers have developed a new technique to generically treat several kinds of cancer, showing tumors grew almost three times less and survival rates reached 100% after just one injection. The method targets cancer cells with alpha radiation, sparing healthy tissue.
Researchers at MedUni Vienna's Department of Thoracic Surgery have made key findings in small-cell lung cancer, including the identification of tumor subgroups associated with varying clinical behaviors. They also propose promising therapeutic strategies for patients with characteristic molecular profiles.
The study found that fiber straightness is a potential biomarker for diagnosing non-small cell lung cancer, while density is a poor prognostic indicator. The researchers also discovered abnormal stiffening of tissues in tumor samples, which may be related to immune system response and tumor progression.
Researchers found that spinal cord stimulation reduced pain response in rats with human lung cancer tissue without compromising paclitaxel effectiveness. The study also showed SCS improved antitumor efficacy of paclitaxel, providing evidence for its potential as a companion treatment.
Researchers discuss rapamycin's potential to delay cancer onset by slowing cell proliferation and tumor progression. The mTOR pathway is involved in both cancer and aging, making rapamycin a promising chemopreventive agent.
Researchers found that neutrophils can be pro- or anti-tumour depending on their surface markers, and those fighting tumours share cytotoxic power with neutrophils in bacterial infections. Blocking these anti-tumour neutrophils eliminates treatment benefits.
Researchers found that immune checkpoint inhibitors increase the mobilization of overlapping tumor-reactive CD8+ T cells, leading to antitumor effects. The diverse subset of T-cell clones plays a key role in this response, with polyclonal clones exhibiting more proliferative potential and contributing to effective treatment outcomes.
Researchers developed a 3D cell culture system to test fibroblast inhibitors with anti-cancer drugs. Combining nintedanib with cisplatin increased the latter's efficacy in suppressing cancer growth and invasion. The study provides a promising tool for preclinical drug testing.
Researchers at the Salk Institute discovered that combining two therapeutic drugs, entinostat and trametinib, can significantly reduce tumor volume and number in mice with LKB1-mutated non-small cell lung cancer. The findings could lead to clinical trials in humans and potentially transform treatment for cancers beyond NSCLC.
A Phase II trial led by researchers from the University of Texas MD Anderson Cancer Center demonstrated that adding ipilimumab to a neoadjuvant combination of nivolumab plus platinum-based chemotherapy resulted in a major pathologic response in half of all treated patients with early-stage non-small cell lung cancer. The treatment also...
Researchers at Kyoto University found that neutrophils instruct macrophages to form a bacteria-permissive microenvironment, which could have implications for cancer treatment. The study suggests that A9, an enzyme expressed in neutrophils, may play a key role in this process.
Researchers at NUS Cancer Science Institute discover FAM3C in tumor-derived extracellular vesicles promotes distant lung tumour colonization. FAM3C enhances cellular transformation and stimulates metastasis potential, offering new therapeutic strategy targets.
A phase 3 clinical trial of nearly 700 patients with early-stage lung cancer found that sublobar resection surgery, removing part of the affected lobe, was as effective as traditional lobectomy in terms of disease-free and overall survival. Patients who underwent sublobar resection also showed modestly better lung function.
A new study published in the International Journal of Radiation Oncology, Biology and Physics found that stereotactic body radiotherapy (SBRT) is an effective treatment for early stage lung neuroendocrine tumors. The three-, six- and nine-year local control rates with SBRT were 97%, 91% and 91%, respectively.
A new study reveals that the immune system mounts a weak response to lung cancer due to an environment created by bacteria in the lymph nodes near the lungs. T-cell responses are suppressed by regulatory T cells and interferon gamma produced in response to commensal bacterial presence.
Researchers identified a subset of mutations within tumor mutation burden that remain persistent and visible to the immune system, increasing likelihood of response to immunotherapy. This finding enables clinicians to more accurately select patients for clinical trials or predict clinical outcomes with immune checkpoint blockade.
Researchers found that a protein called XBP1s enhances tumor survival by suppressing the anti-cancer activity of neighboring immune cells. This discovery could lead to new treatments that overcome this tumor defense mechanism and improve outcomes for lung cancer patients.
A study published in Nature reveals that cancer stem cells' miscommunication with their environment can trigger a self-perpetuating series of events leading to malignancy. Leptin signaling plays a surprising role in this process, which could be blocked to prevent tumor progression.
Researchers identified molecular profiles of tumor matrices around squamous cell lung cancers, finding that altered matrices promote tumour growth and chemotherapy resistance. The study sheds light on why some patients progress well and others don't, and how personalized treatment can be developed.
Researchers have discovered that targeting a specific mutation in fibrolamellar tumors can reduce tumor growth in mice, offering a promising approach to treating this nearly incurable cancer. The findings highlight the potential for novel therapies against an intractable disease.
A retrospective study found that tumor hyaluronan levels are associated with improved time to progression in non-small cell lung cancer patients. HA-high tumors showed a trend towards improved clinical benefit, suggesting its potential as a prognostic biomarker and therapeutic target.
Dual-energy CT (DECT) metrics provide insight into physiologic changes after lung cancer surgery, beyond PFTs and conventional CT. Lung perfusion ratio increases were greater after lobectomy than limited resection.
Researchers discovered a molecular link between disrupted circadian rhythms and lung tumor growth, implicating a cancer-signature gene known as HSF1. Disrupted clocks may trigger lung tumors in individuals with irregular sleep patterns or night shifts.
A new study reveals that different SCLC subtypes have specific molecular characteristics, leading to varying responses to cancer treatment. The research provides a basis for developing targeted and personalized treatment approaches tailored to each subtype.
Scientists at Northwestern University have identified a new gene that activates an aggressive subtype of small-cell lung cancer with no current effective treatment. Deleting this gene kills cancer cells in deadly subtype.
Researchers found that certain fungal species in tumors are linked to inflammation and reduced cell-to-cell adhesion, features associated with late-stage cancer spread. High levels of these fungi may serve as biomarkers for metastasis risk and lead to more effective treatment choices.
A new study provides valuable insights into the roles of B cells and plasma cells in early-stage lung cancer biology, highlighting their influence on tumor development and treatment outcomes. The research also reveals environmental factors and molecular features that contribute to the landscape of infiltrating immune cells.
Researchers have found a promising new combination therapy that uses immunotherapy alongside a drug blocking a common gene mutation in lung cancer. The study suggests this combination may be effective in 'immune hot' tumours, which are more likely to respond.
Researchers at the University of Cincinnati are studying how lipids help fortify lung cancer cells and if targeting them can lead to better outcomes. The team discovered that lipids play a crucial role in cancer cell growth, membrane fortification, and energy production.
Researchers validated a liquid biopsy test as a better predictor of immunotherapy response in lung cancer patients compared to traditional tumor biopsies. The test measures the PD-L1 biomarker in blood, showing improved accuracy in predicting treatment outcomes and survival.
A Brazilian group developed a peptide called Rb4 that triggers necrosis in murine melanoma cells and inhibits the viability of human cancer cells. In mice, Rb4 reduced lung metastasis and slowed subcutaneous melanoma growth, increasing survival by 25%.
Adding immunotherapy to chemotherapy before surgery reduced the risk of recurrence and death in lung cancer patients by 37%, according to a phase III trial. The treatment also led to a nearly twelvefold increase in pathological complete response, with 24% of patients achieving no active cancer remaining when the tumor was removed.
Raising awareness about cardiac radiation exposure reduced the number of patients receiving high heart doses in lung cancer patients. The study found that standardized cardiac dose constraints improved patient care without minimizing tumor treatment or increasing dosage to other at-risk organs.
Researchers developed a method to identify aggressive early-stage lung cancers and target drugs to tumors likely to respond. They used genomics network models and identified signature genes associated with tumor invasiveness.
A Spanish national registry study found that over half of diagnosed lung cancer patients undergo biomarker testing, with a significant increase over the last five years. Nearly half of patients with positive test results received targeted treatment.
Researchers at Weill Cornell Medicine have found that an enzyme called ART1 can modify a receptor on tumor-fighting immune cells, triggering their death. Blocking ART1 increased the presence of these immune cells within tumors and slowed or stopped tumor growth in animal models.
Researchers developed a novel genetic barcode system to mark cancer cells with different gene modifications and image their characteristics. The Perturb-map platform identified specific genes controlling lung tumor growth, immune composition, and response to immunotherapy, offering new approaches for targeting anti-cancer drugs.
Researchers at UVA Cancer Center have made a groundbreaking discovery about the EP300 gene and its role in small-cell lung cancer. The study found that the gene makes a protein with properties that can both foster and prevent tumor formation, providing a new potential target for treatment.
A recent study published in Developmental Cell reveals that Kras mutation causes chromatin rearrangement, leading to stem-like cell regeneration and tumor onset. The team discovered a protein complex called AP-1 as the mediator of this process, which can be targeted with small-molecule drugs.
Researchers at Children's Hospital of Philadelphia define a 3-tiered molecular classification system for pediatric differentiated thyroid cancer, where fusion oncogenes are associated with more invasive disease and lower remission rates. The study contrasts findings from adults, who have a two-tiered system based on BRAF mutations.
A recent study found that a substantial decline in lung cancer deaths is associated with earlier diagnosis of lung cancer through increased screening via computed tomography (CT) and follow-up scans. This approach can lead to surgical interventions, which can often be curative for precancerous nodules.
Researchers have discovered a nanoparticle therapeutic that enhances cancer immunotherapy and treats malignant pleural effusion. The treatment targets the immune system to recognize and eliminate cancer cells, improving survival rates and quality of life for patients.
Researchers at Saarland University have discovered that the lipid and cholesterol metabolism of immune cells collaborating with tumour cells is severely compromised compared to tumour tissue. This finding suggests a possible explanation for why cholesterol-lowering drugs are ineffective against non-small-cell lung carcinoma.
Researchers discovered a new biomarker, inactive AMPK (lo-P-AMPK), that may predict immune evasion in lung cancer. The finding could enable better personalized care for lung cancer patients by identifying those most likely to benefit from immunotherapies.
Researchers found that certain T cells stop working before entering the tumor due to changes in gene expression, making ICB therapies less effective. Combining ICB with other forms of immunotherapy targeting different aspects of T cell function may improve response rates for non-small cell lung cancer patients.
A new study finds that high-dose radiation therapy can lengthen progression-free survival for people with advanced lung cancer when systemic therapy has not fully halted tumor growth or spread. Stereotactic body radiation therapy (SBRT) shows promise in treating oligoprogressive, metastatic lung and breast cancer.
A woman with non-small cell lung cancer experienced a 76% tumor reduction after taking CBD oil for 2.5 years, raising hopes for alternative cancer treatments. However, more research is needed to confirm the mechanism of action and potential side effects.
A retrospective cohort study of 27 patients with sarcoma lung metastases found high primary technical success rates for percutaneous image-guided microwave and cryoablation. The treatment modality and tumor location did not affect local progression, and smaller tumors showed lower cumulative incidence of local progression.
MIT researchers have found that vaccinating against certain cancer proteins can boost the overall T cell response and help to shrink tumors in mice. The study identifies specific neoantigens that, when targeted with a vaccine, can reawaken dormant T cell populations and lead to tumor regression.
Researchers developed a treatment using cowpea mosaic virus nanoparticles that target lung tumors, slowing tumor growth and preventing cancer spread. The treatment showed efficacy against aggressive cancer cell lines and may offer protection to patients at high risk of metastatic disease.
Eosinophils, a type of white blood cell, play a crucial role in destroying malignant tumors by recruiting T-cells and releasing destructive proteins. The study, published in Cancer Research, reveals that eosinophils combat cancer effectively but require the help of T-cells to do so.
The IASLC molecular subcommittee has accumulated molecular biomarker data to complement TNM-based prognostication in lung cancer. The dataset includes 64,434 cases from 2010-2019 and 14 countries, with EGFR being the most common biomarker.
Researchers have developed an AI program that can spot signs of lung cancer up to a year before diagnosis using CT scans. The program was trained on 888 patients and tested on a separate set of 1179 patients, achieving a 97% accuracy rate in detecting malignant tumours.
Scientists investigated a method to enhance immunotherapy for lung cancer and found that combining it with certain chemotherapy drugs could eliminate harmful immune cells. This approach showed promising results in preclinical studies, inducing the regression of about 70% of tumors.
A new study published in the American Journal of Pathology uses Fast IR imaging-based AI to identify tumor type in lung cancer, providing a promising diagnostic method for future testing and treatment prediction. The analysis takes only half an hour, offering a significant improvement over current methods.
Researchers at Mount Sinai Hospital discovered that early-stage lung cancer tumors hijack immune cells called tissue-resident macrophages to facilitate their invasion of lung tissue. This process allows the tumor to evade the immune system and grow into more deadly stages of cancer.
Researchers created a spatial atlas of early-stage lung cancer and normal lung tissue at single-cell resolution, providing insights into tumor development and immune cell interactions. The study identified CD24 as a new immunotherapy target for lung cancer treatment, correlating with poor clinical outcomes and shortened survival.
Researchers at McMaster University have developed a novel combination of two immunotherapies that induces robust tumour destruction against lung cancer. The new treatment uses one form of therapy to kill cancer cells and triggers changes that enable the second therapy to finish the job.
Scientists have identified a new metabolic vulnerability in highly aggressive non-small cell lung cancer (NSCLC) tumors containing mutations in KRAS and LKB1. The hexosamine biosynthesis pathway is activated in these tumors, providing a potential target for therapy.
Researchers develop a new approach to treating lung metastasis by delivering chemokine CXCL10 via red blood cells, stimulating the immune system to attack tumors. Treatment with erythrocyte-anchored systemic immunotherapy (EASI) halts tumor growth and induces an immune response in mice.